Last updated: April 25, 2026
Who Supplies Amikacin Sulfate to Pharma Markets?
Amikacin sulfate is a well-established small-molecule antibiotic. Commercial supply typically runs through (1) active pharmaceutical ingredient (API) manufacturers producing “amikacin sulfate” and (2) contract manufacturers and distributors sourcing API and supplying finished dosage forms or bulk amikacin sulfate to downstream firms.
The supplier landscape depends on the market (US, EU, India/China, MENA), regulatory posture (DMF/CEP status), and the intended use (API vs sterile drug product). This overview enumerates the supplier categories and the principal public-source supplier entities that repeatedly appear in regulated supply chains for amikacin sulfate.
What Supplier Categories Exist for Amikacin Sulfate?
-
API manufacturers (amikacin sulfate active)
- Produce and sell amikacin sulfate API for formulation.
- Commonly support regulatory submissions via DMFs (US) and/or CEP dossiers (EU).
-
Finished-dose drug product manufacturers
- Produce injectable amikacin products (typically sterile vials).
- Source API from one or more qualified API suppliers.
-
Distributors and traders
- Move API and bulk finished products into local markets.
- Often hold inventory and manage import-to-country regulatory requirements.
-
Contract manufacturing organizations (CMOs)
- Manufacture finished sterile products or non-sterile intermediates under contract.
- Source API from qualified vendors.
Which Companies Are Documented Suppliers of Amikacin Sulfate (API or Drug Product)?
API and bulk amikacin sulfate suppliers (commonly listed in regulatory and commercial supply chains)
The following entities are repeatedly associated with amikacin sulfate supply in pharma distribution and regulatory contexts:
- FDC Limited (India)
- Hetero Labs / Hetero Drugs (India)
- Pfizer (licensed production historically in some markets, depending on product line and geography)
- Siegfried (Europe, depending on dosage form manufacture and sourcing)
- Mylan (now Viatris) (US market presence historically for sterile injectable categories, dosage-form dependent)
- Sun Pharmaceutical Industries (India)
- Intas Pharmaceuticals (India)
- Sandoz (EU/global, dosage-form dependent)
- Accord Healthcare (EU/UK, dosage-form dependent)
- Hospira (Pfizer) (historical injectable supply via legacy portfolio, dosage-form dependent)
Drug product manufacturers (amikacin sulfate injections)
For injectable antibiotics, supplier lists are often dominated by manufacturers of sterile vials and finished drug products. The major publicly visible supplier set in many geographies includes:
- Fresenius Kabi (sterile injectables; specific product line and strength vary by market)
- Hospira / Pfizer (legacy injectable portfolio in multiple markets)
- Sandoz
- Mylan / Viatris
- Teva (market-dependent for generics)
- Accord Healthcare
- Intas
- Hetero
- Sun Pharma
- Dr. Reddy’s Laboratories (market-dependent)
Note: For injectables, the “supplier” in commercial practice is often the finished-dose manufacturer, not the API producer. Many firms source amikacin sulfate API from multiple vendors and change sources over time based on qualification and supply continuity.
How to Identify the Right “Supplier” for Your Use Case (API vs Injection)?
If you need amikacin sulfate API
Your supplier target is an API manufacturer with:
- A regulator-compatible dossier strategy (DMF for the US, CEP for the EU).
- Batch traceability aligned to GMP.
- Specification support for amikacin sulfate substance (salt form, polymorph/hydrate form where applicable).
If you need amikacin sulfate injection (finished sterile vials)
Your supplier target is a sterile injectable manufacturer that can deliver:
- Strength-specific vial formats (e.g., commonly 50 mg/mL or 500 mg/2 mL types, market dependent).
- Sterility assurance, filled-and-finished controls, and labeled presentation compliant with local authority.
What Specifications Do Suppliers Commonly Quote for Amikacin Sulfate?
Suppliers generally quote substance or product specs that include:
- Chemical identity (amikacin sulfate salt form)
- Assay/potency
- Impurities (related substances and residuals)
- Solubility/clarity (for solution products)
- Sterility and endotoxin (for injections)
- Microbial limits (for non-sterile presentations)
Because suppliers quote these in their regulatory dossiers and COAs, the exact acceptance criteria varies by filing and jurisdiction.
Where Supplier Lists Are Most Verifiable (Public Sources)?
Regulatory and listing sources typically used to confirm supplier identity
- US FDA Drug Shortages / labeling databases for product suppliers in the US
- FDA Orange Book (for approved drug products; points to NDA holders and labeled manufacturers)
- EMA/EC consolidated medicinal products databases for EU-marketed products
- CEP status repositories (for EU API confirmations where applicable)
- DMF listings (for US API submissions, where publicly indexed)
These sources let you map:
- Finished product manufacturer (label holder)
- Product strength and dosage form
- Market-specific supply presence
Supplier Landscape by Region (Commercial Reality)
India
- Large generic sterile and API capability base.
- Common presence of multiple players producing injectable generics and supplying API into global distribution channels.
China
- Significant API manufacturing footprint for amikacin sulfate.
- Strong capacity for bulk API supply into export markets.
EU/UK
- Finished-dose sterile injectable manufacturing is often concentrated among established generics and hospital-focused suppliers.
- API sourced both from domestic and international CMOs depending on filing strategy.
US
- Product-level suppliers dominate public visibility.
- API supplier identity is typically validated via DMF linkage and quality agreements rather than consumer-facing catalogs.
Key Takeaways
- Amikacin sulfate supply is split between API manufacturers and finished-dose sterile injectable manufacturers; the “supplier” you need depends on whether you are buying substance or injection.
- In regulated supply chains, the supplier list most visibly reflects finished-dose manufacturers in local markets, while API suppliers are confirmed through dossier-linked quality documentation.
- Major repeat-appearances in amikacin sulfate supply include large India-based generics and sterile injectable makers, plus established EU/US players for finished products (market- and strength-dependent).
FAQs
1) Is amikacin sulfate typically supplied as API or only as finished injection?
It is supplied as both, with injections dominating in regulated procurement for hospitals and distributors, and API dominating when formulation or sterile compounding is performed by branded/generic manufacturers.
2) Which is the better target for supply security: API manufacturers or finished-dose manufacturers?
If your operation formulates or fills product, API manufacturers matter most. If you purchase finished vials, finished-dose manufacturers determine supply continuity.
3) Do finished-dose suppliers always use the same amikacin sulfate API vendor?
No. Qualified suppliers often change due to qualification cycles, lot availability, and quality agreement terms.
4) How do pharma buyers validate an amikacin sulfate supplier?
They validate through regulatory dossier references (DMF/CEP), GMP status, historical COA/quality history, and contract quality agreement controls for impurities and residuals.
5) Why does supplier availability differ by country?
Product approvals, labeling requirements, and import authorizations vary by jurisdiction, which shifts which finished-dose manufacturers can legally supply a given market.
References
[1] US Food and Drug Administration (FDA). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
[2] European Medicines Agency (EMA). Medicines database and EPAR/SmPC records (marketed products for amikacin sulfate injections).
[3] European Directorate for the Quality of Medicines and HealthCare (EDQM). CEP database for substances (as available publicly for relevant entries).
